Furthermore, using a novel FAK inhibitor (IN10018, received fast track designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation by the China National Medical Products Administration) to inhibit the activation of CAFs could break the physical barrier, effectively recruit effector immune cells into the TME, thus boosting anticancer immune response in KL lung cancer mouse models. This evidence concerns the gene PTK2 and lung carcinoma.